Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial

二甲双胍 医学 血糖性 超重 体质指数 内科学 2型糖尿病 糖尿病 内分泌学 临床终点 肥胖 胃肠病学 随机对照试验
作者
Linong Ji,Hongmei Li,Xiaohui Guo,Li Yan,Renming Hu,Zhengying Zhu
出处
期刊:PLOS ONE [Public Library of Science]
卷期号:8 (2): e57222-e57222 被引量:42
标识
DOI:10.1371/journal.pone.0057222
摘要

BACKGROUND: Differences exist between treatment recommendations regarding the choice of metformin as first-line therapy for type 2 diabetes patients according to body mass index (BMI). This study compared the efficacy of metformin monotherapy among normal-weight, overweight, and obese patients with newly diagnosed type 2 diabetes. METHODS: In this prospective, multicenter, open-label study in China, patients aged 23-77 years were enrolled 1∶1:1 according to baseline BMI: normal-weight (BMI 18.5-23.9 kg/m(2); n = 125); overweight (BMI 24.0-27.9 kg/m(2); n = 122) or obese (BMI ≥28 kg/m(2); n = 124). Extended-release metformin was administered for 16 weeks (500 mg/day, up-titrated weekly to a maximum 2,000 mg/day). The primary efficacy endpoint was the effect of baseline BMI on glycemic control with metformin monotherapy, measured as the change from baseline in glycosylated hemoglobin (HbA1c) at week 16 compared among BMI groups using ANCOVA. Other endpoints included comparisons of metformin's effects on fasting plasma glucose (FPG), lipid levels and body weight. RESULTS: Mean HbA1c decreases at week 16, adjusted for baseline values, were -1.84%, -1.78% and -1.78% in normal-weight, overweight and obese patients, (P = 0.664); body weight decreased by 2.4%, 3.9% and 3.5%, respectively. FPG levels decreased similarly over time in all BMI groups (P = 0.461) and changes from baseline in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) did not differ significantly among BMI groups at week 16 (P = 0.143 and 0.451, respectively). CONCLUSIONS: Baseline BMI had no impact on glycemic control, weight change or other efficacy measures with metformin monotherapy. These data suggest that normal-weight type 2 diabetes patients would derive the same benefits from first-line treatment with metformin as overweight and obese patients, and are not at increased risk of excess weight loss. TRIAL REGISTRATION: ClinicalTrials.gov NCT00778622.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
希望天下0贩的0的应助被yjw采纳,获得10
刚刚
背后白柏完成签到 ,获得积分10
刚刚
12发布了新的文献求助10
1秒前
syvshc的应助被周一采纳,获得10
2秒前
杨媛发布了新的文献求助10
2秒前
2秒前
2秒前
whj发布了新的文献求助10
3秒前
3秒前
4秒前
4秒前
5秒前
gwo完成签到,获得积分10
5秒前
冷傲的如凡完成签到,获得积分10
6秒前
yuan发布了新的文献求助10
7秒前
如初发布了新的文献求助10
7秒前
自强不息完成签到,获得积分10
7秒前
椿人完成签到 ,获得积分10
8秒前
8秒前
8秒前
杨小鸿发布了新的文献求助10
9秒前
研友_VZG7GZ的应助被动人的向松采纳,获得30
9秒前
深情安青的应助被动人的向松采纳,获得30
9秒前
9秒前
10秒前
AUGS酒发布了新的文献求助10
11秒前
来来完成签到,获得积分10
11秒前
12秒前
挚友发布了新的文献求助10
13秒前
14秒前
勤劳水壶完成签到,获得积分10
14秒前
14秒前
一土完成签到,获得积分10
14秒前
crispyvelvet发布了新的文献求助30
15秒前
ruuu发布了新的文献求助10
15秒前
15秒前
15秒前
彪壮的斩完成签到 ,获得积分10
16秒前
16秒前
文献狗发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193729
求助须知:如何正确求助?哪些是违规求助? 9579876
关于积分的说明 21868333
捐赠科研通 7793519
什么是DOI,文献DOI怎么找? 3437414
关于科研通互助平台的介绍 2560856
邀请新用户注册赠送积分活动 2484216